• 1
    Blot W. Esophageal cancer trends and risk factors. Semin Oncol. 1994; 21: 403-410.
  • 2
    Spechler SJ. Barrett's esophagus: a molecular perspective. Curr Gastroenterol Rep. 2005; 7: 177-181.
  • 3
    Chen X, Yang CS. Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis. 2001; 22: 1119-1129.
  • 4
    Barak N, Ehrenpreis ED, Harrison JR, Sitrin MD. Gastro-oesophageal reflux disease in obesity: pathophysiological and therapeutic considerations. Obes Rev. 2002; 3: 9-15.
  • 5
    Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999; 284: 1362-1625.
  • 6
    Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999; 284: 1365-1368.
  • 7
    Xu X-C, Liu X, Tahara E, Lippman SM, Lotan R. Expression and up-regulation of retinoic acid receptor-beta is associated with retinoid sensitivity and colony formation in esophageal cancer cell lines. Cancer Res. 1999; 59: 2477-2483.
  • 8
    Smith KJ, O'Brien SM, Smithers BM, et al. Interactions among smoking, obesity, and symptoms of acid reflux in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev. 2005; 14: 2481-2486.
  • 9
    Lindblad M, Rodriguez LA, Lagergren J. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control. 2005; 16: 285-294.
  • 10
    Xu X-C. Risk factors and altered gene expression in esophageal cancer. In: Verma M, ed. Cancer Epidemiology. New York: Humana Press; 2009: 335-360.
  • 11
    Jaiswal K, Lopez-Guzman C, Souza RF, Spechler SJ, Sarosi GA Jr. Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non-neoplastic Barrett's cell line. Am J Physiol Gastrointest Liver Physiol. 2006; 290: G335-G342.
  • 12
    Looby E, Abdel-Latif MM, Athie-Morales V, Duggan S, Long A, Kelleher D. Deoxycholate induces COX-2 expression via Erk1/2, p38-MAPK and AP-1-dependent mechanisms in esophageal cancer cells [serial online]. BMC Cancer. 2009; 9: 190.
  • 13
    Bernstein H, Bernstein C, Payne CM, Dvorak K. Bile acids as endogenous etiologic agents in gastrointestinal cancer. World J Gastroenterol. 2009; 15: 3329-3340.
  • 14
    Wu J, Gong J, Geng J, Song Y. Deoxycholic acid induces the overexpression of intestinal mucin, MUC2, via NF-kB signaling pathway in human esophageal adenocarcinoma cells [serial online]. BMC Cancer. 2008; 8: 333.
  • 15
    Li M, Song S, Lippman SM, et al. Induction of retinoic acid receptor-β suppresses cyclooxygenase-2 expression in esophageal cancer cells. Oncogene. 2002; 21: 411-418.
  • 16
    Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science. 2001; 294: 1866-1870.
  • 17
    Houle B, Leduc F, Bradley WE. Implication of RARB in epidermoid (squamous) lung cancer. Genes Chromosomes Cancer. 1991; 3: 358-366.
  • 18
    Ren M, Pozzi S, Bistulfi G, et al. Impaired retinoic acid (RA) signal leads to RARbeta2 epigenetic silencing and RA resistance. Mol Cell Biol. 2005; 25: 10591-10603.
  • 19
    Song S, Guan B, Men T, Hoque A, Lotan R, Xu X-C. Antitumor effect of retinoic acid receptor-β2 associated with suppression of cyclooxygenase-2. Cancer Prevent Res. 2009; 2: 274-280.
  • 20
    Song S, Lippman SM, Zou Y, Ye X, Ajani JA, Xu X-C. Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-β2 expression. Oncogene. 2005; 24: 8268-8276.
  • 21
    Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 1996; 10: 940-954.
  • 22
    Liang ZD, Lippman SM, Wu TT, et al. RRIG1 mediates effects of retinoic acid receptor-β2 on tumor cell growth and gene expression through binding to and inhibiting RhoA. Cancer Res. 2006; 66: 7111-7118.
  • 23
    Huang J, Liang ZD, Wu TT, et al. Tumor-suppressive effect of retinoid receptor-induced gene-1 (RRIG1) in esophageal cancer. Cancer Res. 2007; 67: 1589-1593.
  • 24
    Song S, Xu X-C. Effect of benzo[a]pyrene diol epoxide on expression of retinoic acid receptor-beta in immortalized esophageal epithelial cells and esophageal cancer cells. Biochem Biophys Res Commun. 2001; 281: 872-877.
  • 25
    Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009; 89: 147-191.
  • 26
    Wang YD, Yang F, Chen WD, et al. Farnesoid X receptor protects liver cells from apoptosis induced by serum deprivation in vitro and fasting in vivo. Mol Endocrinol. 2008; 22: 1622-1632.
  • 27
    Modica S, Murzilli S, Salvatore L, Schmidt DR, Moschetta A. Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res. 2008; 68: 9589-9594.
  • 28
    Swales KE, Korbonits M, Carpenter R, Walsh DT, Warner TD, Bishop-Bailey D. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res. 2006; 66: 10120-10126.
  • 29
    Journe F, Durbecq V, Chaboteaux C, et al. Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients. Breast Cancer Res Treat. 2009; 115: 523-535.
  • 30
    De Gottardi A, Dumonceau JM, Bruttin F, et al. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro [serial online]. Mol Cancer. 2006; 5: 48.
  • 31
    Das A, Yaqoob U, Mehta D, Shah VH. FXR promotes endothelial cell motility through coordinated regulation of FAK and MMP-9. Arterioscler Thromb Vasc Biol. 2009; 29: 562-570.
  • 32
    Capello A, Moons LM, Van de Winkel A, et al. Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus. Am J Gastroenterol. 2008; 103: 1510-1516.
    Direct Link:
  • 33
    Lee JY, Lee KT, Lee JK, et al. Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion. Br J Cancer. 2011; 104: 1027-1037.
  • 34
    Shishodia S, Sethi G, Ahn KS, Aggarwal BB. Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products. Biochem Pharmacol. 2007; 74: 118-130.
  • 35
    Urizar NL, Moore DD. GUGULIPID: a natural cholesterol lowering agent. Annu Rev Nutr. 2003; 23: 303-313.
  • 36
    Kim ES, Hon SY, Lee HK, et al. Guggulsterone inhibits angiogenesis by blocking STAT3 and VEGF expression in colon cancer cells. Oncol Rep. 2008; 20: 1321-1327.
  • 37
    Urizar NL, Liverman AB, Dodds DT, et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 2002; 296: 1703-1706.
  • 38
    Cui J, Huang L, Zhao A, Lew JL, Sahoo S, Meinke PT. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J Biol Chem. 2003; 278: 10214-10220.
  • 39
    Jaiswal K, Tello V, Lopez-Guzman C, et al. Bile salt exposure causes phosphatidyl-inositol-3-kinase-mediated proliferation in a Barrett's adenocarcinoma cell line. Surgery. 2004; 136: 160-168.
  • 40
    Jenkins GJ, Harries K, Doak SH, et al. The bile acid deoxycholic acid (DCA) at neutral pH activates NF-kappaB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis. 2004; 25: 317-323.